A ligand’s-eye view of protein binding

Docking tools created for structure-based design and virtual screening have also been used to automate ligand alignment for comparative molecular field analysis (CoMFA). Models based on such alignments have been compared with those obtained based solely on shared ligand substructures, but such comparisons have generally failed to distinguish between conformational specification (alignment in the internal coordinate space) and embedding in a shared external frame of reference (Cartesian alignment). Here, large sets of inhibitors were docked into two cyclooxygenase and two reverse transcriptase crystal structures, and the poses generated were evaluated in terms of the CoMFA models they produced. Realigning the conformers obtained by docking by rigid-body rotation and translation to overlay their common substructures improved model statistics and interpretability, provided the protein structure used for docking was reasonably appropriate to the ligands being considered.

[1]  Paul J Lewi,et al.  Structure based activity prediction of HIV-1 reverse transcriptase inhibitors. , 2005, Journal of medicinal chemistry.

[2]  R. Clark,et al.  Consensus scoring for ligand/protein interactions. , 2002, Journal of molecular graphics & modelling.

[3]  G Klebe,et al.  On the prediction of binding properties of drug molecules by comparative molecular field analysis. , 1993, Journal of medicinal chemistry.

[4]  Ronan Bureau,et al.  Comparative molecular field analysis of CCK-A antagonists using field-fit as an alignment technique. A convenient guide to design new CCK-A ligands , 1992, J. Comput. Aided Mol. Des..

[5]  Ki Hwan Kim,et al.  Outliers in SAR and QSAR: Is unusual binding mode a possible source of outliers? , 2007, J. Comput. Aided Mol. Des..

[6]  Ingo Muegge,et al.  3D-Quantitative Structure Activity Relationships of Biphenyl Carboxylic Acid MMP-3 Inhibitors: Exploring Automated Docking as Alignment Method , 2001 .

[7]  Márcia M. C. Ferreira,et al.  A structure–activity relationship study of HEPT-analog compounds with anti-HIV activity , 2000 .

[8]  Zhigang Zhou,et al.  CoMFA 3D-QSAR Analysis of HIV-1 RT Nonnucleoside Inhibitors, TIBO Derivatives Based on Docking Conformation and Alignment , 2004, J. Chem. Inf. Model..

[9]  David A. Frenkel,et al.  CoMFA validation of the superposition of six classes of compounds which block GABA receptors non-competitively , 1993, J. Comput. Aided Mol. Des..

[10]  Matthew Clark,et al.  The Probability of Chance Correlation Using Partial Least Squares (PLS) , 1993 .

[11]  Carmen Almansa,et al.  Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site? , 2003, Journal of medicinal chemistry.

[12]  Ajay N. Jain Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[13]  Juan M. Luco,et al.  QSAR Based on Multiple Linear Regression and PLS Methods for the Anti-HIV Activity of a Large Group of HEPT Derivatives , 1997, J. Chem. Inf. Comput. Sci..

[14]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[15]  Anderson Coser Gaudio,et al.  HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures , 2002, J. Comput. Aided Mol. Des..

[16]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[17]  D. Lesieur,et al.  Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis. , 2001, Journal of medicinal chemistry.

[18]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[19]  C. Monneret,et al.  A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition. , 1997, Journal of medicinal chemistry.

[20]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[21]  Jonas Boström,et al.  Conformational energy penalties of protein-bound ligands , 1998, J. Comput. Aided Mol. Des..

[22]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[23]  Richard T. Walker,et al.  Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.

[24]  S Shigeta,et al.  A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). , 1991, Journal of medicinal chemistry.

[25]  Peter C. Fox,et al.  Statistical variation in progressive scrambling , 2004, J. Comput. Aided Mol. Des..

[26]  Juan J Perez,et al.  Differential binding mode of diverse cyclooxygenase inhibitors. , 2002, Journal of molecular graphics & modelling.

[27]  Asit K Chakraborti,et al.  Computer-aided design of non sulphonyl COX-2 inhibitors: an improved comparative molecular field analysis incorporating additional descriptors and comparative molecular similarity indices analysis of 1,3-diarylisoindole derivatives. , 2003, Bioorganic & medicinal chemistry.

[28]  P. Charifson,et al.  Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding. , 2004, Journal of medicinal chemistry.

[29]  Yvonne C. Martin,et al.  3D QSAR: current state, scope, and limitations , 1998 .

[30]  Supa Hannongbua,et al.  3D-Quantitative Structure-Activity Relationships of HEPT Derivatives as HIV-1 Reverse Transcriptase Inhibitors, Based on Ab Initio Calculations , 2001, J. Chem. Inf. Comput. Sci..

[31]  G. Klebe,et al.  DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. , 2002, Journal of medicinal chemistry.

[32]  D I Stuart,et al.  Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. , 1999, Journal of medicinal chemistry.

[33]  Gregory W. Kauffman,et al.  QSAR and k-Nearest Neighbor Classification Analysis of Selective Cyclooxygenase-2 Inhibitors Using Topologically-Based Numerical Descriptors , 2001, J. Chem. Inf. Comput. Sci..

[34]  R. Webster Homer,et al.  SYBYL Line Notation (SLN): A Versatile Language for Chemical Structure Representation , 1997, J. Chem. Inf. Comput. Sci..

[35]  D. Lesieur,et al.  Comparative Molecular Field Analysis of Selective Cyclooxygenase‐2 (COX‐2) Inhibitors , 2000 .

[36]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[37]  R. Pouplana,et al.  Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs , 2002, J. Comput. Aided Mol. Des..

[38]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[39]  Luc Morin-Allory,et al.  2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database , 2004, J. Chem. Inf. Model..

[40]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[41]  Bart De Corte,et al.  From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2005 .

[42]  Gerhard Klebe,et al.  Different approaches toward an automatic structural alignment of drug molecules: Applications to sterol mimics, thrombin and thermolysin inhibitors , 1994, J. Comput. Aided Mol. Des..

[43]  E. Coutinho,et al.  A CoMFA study of COX-2 inhibitors with receptor based alignment. , 2004, Journal of molecular graphics & modelling.

[44]  Gautam R. Desiraju,et al.  Computer-aided design of selective cox-2 inhibitors: comparative molecular field analysis and docking studies of some 3,4-diaryloxazolone derivatives , 2001 .

[45]  R. Cramer,et al.  Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.

[46]  Tudor I. Oprea,et al.  Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. , 1994, Journal of medicinal chemistry.

[47]  Jonas Boström,et al.  Reproducing the conformations of protein-bound ligands: A critical evaluation of several popular conformational searching tools , 2001, J. Comput. Aided Mol. Des..

[48]  Thierry Langer,et al.  On the Use of Chemical Function-Based Alignments as Input for 3D-QSAR , 1998, J. Chem. Inf. Comput. Sci..

[49]  Shashidhar N. Rao,et al.  Partially Unified Multiple Property Recursive Partitioning (PUMP-RP) Analyses of Cyclooxygenase (COX) Inhibitors , 2003, J. Chem. Inf. Comput. Sci..

[50]  R T Walker,et al.  Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. , 1992, Journal of medicinal chemistry.

[51]  Erik De Clercq,et al.  Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future , 2004, Chemistry & biodiversity.

[52]  A. M. Myers,et al.  Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor. , 1994, Journal of medicinal chemistry.

[53]  Tudor I. Oprea,et al.  Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. , 1993, Journal of medicinal chemistry.

[54]  Garland R. Marshall,et al.  3D-QSAR of angiotensin-converting enzyme and thermolysin inhibitors: A comparison of CoMFA models based on deduced and experimentally determined active site geometries , 1993 .

[55]  A Tropsha,et al.  Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. , 1995, Journal of medicinal chemistry.

[56]  Ajay N. Jain Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[57]  Mehdi Jalali-Heravi,et al.  Use of Artificial Neural Networks in a QSAR Study of Anti-HIV Activity for a Large Group of HEPT Derivatives , 2000, J. Chem. Inf. Comput. Sci..

[58]  Robert D. Clark,et al.  Boosted leave-many-out cross-validation: the effect of training and test set diversity on PLS statistics , 2003, J. Comput. Aided Mol. Des..

[59]  José L. Medina-Franco,et al.  Docking-based CoMFA and CoMSIA studies of non-nucleoside reverse transcriptase inhibitors of the pyridinone derivative type , 2004, J. Comput. Aided Mol. Des..

[60]  Osman F. Güner,et al.  Pharmacophore perception, development, and use in drug design , 2000 .

[61]  Ruisheng Zhang,et al.  QSAR and classification models of a novel series of COX-2 selective inhibitors: 1, 5-diarylimidazoles based on support vector machines , 2004, J. Comput. Aided Mol. Des..

[62]  Sivaprakasam Prasanna,et al.  QSAR Analysis of 2,3‐Diaryl Benzopyrans/Pyrans as Selective COX‐2 Inhibitors Based on Semiempirical AM1 Calculations , 2004 .